All Posts By

Allison Sit

Dermatologic Effects of Vaping: From the ODAC Poster Hall

By Medical Dermatology

dermatologic effects of vaping

Electronic cigarette use is increasing in the U.S., rising from 4.5% in 2019 to 6.5% in 2023. Although often perceived as safer than traditional smoking, vaping exposes users to carcinogens, volatile compounds, and heavy metals, and its long-term health effects are not fully known. A scoping review presented as a poster at ODAC examines the dermatologic and oral health impacts of vaping.

In an interview with Next Steps in Derm, poster author Julianna Gregory, BSN, shares that the most common findings involved the face and oral cavity. Patients developed persistent oral ulcerations that often improved only after stopping vaping. Facial effects included irritant and allergic contact dermatitis of the lips, perioral skin, cheeks, and eyelids, sometimes linked to metal allergens such as nickel from device components. Vaping was also reported to exacerbate inflammatory and autoimmune skin diseases, including discoid lupus.

Beyond the face, vaping was associated with urticaria and diffuse inflammatory eruptions on the trunk and extremities, suggesting systemic immune activation. Hand dermatitis was also reported due to repeated contact with devices and e-liquid residue. A case of post-surgical free flap compromise highlighted potential vasoconstrictive effects of vaping and raised concerns about impaired wound healing, similar to traditional smoking.

Importantly, dermatologic reactions were reported even with nicotine-free products, indicating that other constituents—such as flavorings, propylene glycol, glycerin, thermal byproducts, and device-derived materials—can act as irritants, allergens, or immune triggers.

Clinicians should routinely ask about vaping as part of the dermatologic history, consider it in unexplained or treatment-resistant conditions (especially involving the face, hands, or oral mucosa), and counsel patients on cessation, including in perioperative settings. The findings also highlight the need for better documentation of vaping behaviors and greater awareness of its potential cutaneous risks.

AD and Regional Eczemas: ODAC in the News

By ODAC Sessions

AD and regional eczemas

At the ODAC Dermatology Conference, Peter Lio, MD, FAAD, shared an updated, patient-centered overview of atopic dermatitis (AD) and regional eczemas, integrating emerging science with real-world clinical strategies.

As noted in an article by The Dermatology Digest, Dr. Lio emphasized AD and regional eczemas are self-perpetuating disorders involving the skin barrier, immune system, microbiome, and sensory nerves. He outlined the epithelial barrier hypothesis and the concept of epicutaneous sensitization. Early, proactive intervention was framed as essential to preventing chronic inflammation, infections, and subsequent disease.

On therapy, Dr. Lio reviewed the expanding role of non-steroidal topical agents, noting their usefulness in sensitive areas and for patients who want a non-steroidal option. He also reinforced the value of adjunctive strategies such as wet wrap therapy. For systemic treatment, he discussed biologics and oral JAK inhibitors, highlighting evidence that dupilumab can uniquely improve the skin microbiome in moderate-to-severe AD. Shared decision-making was a central theme, with Dr. Lio presenting his ESTAR framework to help align treatment choices with patient priorities, and sharing the importance of written action plans.

Finally, Dr. Lio addressed topical steroid withdrawal as a legitimate and evolving diagnosis. He noted that formal diagnostic criteria are forthcoming, signaling progress toward clearer guidance for clinicians.

Evaluating Skin Findings of Systemic Disease

By ODAC Sessions

skin findings of systemic disease

At the 2026 ODAC Dermatology Conference, attendees had the opportunity to learn about evaluating skin findings of systemic disease from Olayemi Sokumbi, MD, FAAD, professor of dermatology and laboratory medicine & pathology at Mayo Clinic. Dr. Sokumbi shared her expertise about evaluating skin findings that may occur in the context of systemic illness, emphasizing a structured derm-dermpath approach. Through two illustrative cases, she demonstrated how the skin serves as an early window to systemic disease and how clinicopathologic correlation (CPC) is integral to establishing the correct diagnosis.

Case 1:

Dr. Sokumbi described a gentleman in his 50s who presented with skin-colored papules on the ears accompanied by joint pains. The presence of concurrent systemic symptoms raised suspicion for an underlying systemic process, prompting a skin biopsy. Histopathology revealed foamy xanthomatous histiocytes, suggesting a non-Langerhans cell histiocytosis with inflammatory arthritis such as Erdheim-Chester disease (EDC). However, at least half of cases of EDC cases demonstrate a BRAF V600E mutation.1 Staining of this skin biopsy was negative for this mutation, prompting Dr. Sokumbi to return to the bedside and broaden the differential diagnosis. Subsequent physical examination revealed periungual papules and nodules, in a characteristic “coral beading” pattern, leading to the diagnosis of multicentric reticulohistiocytosis (MRH), a condition also associated with severe polyarthritis. The histopathologic pitfall requiring CPC was the presence of xanthomatized histiocytes, which are typical for EDC and underrecognized in MRH due to the rarity of this finding. Accurate diagnosis carries significant clinical implications, as MRH has a strong association with solid organ malignancy and requires therapeutic approaches distinct from those used in EDC.

Case 2:

Dr. Sokumbi presented the case of a young lady with diffuse cutaneous hyperpigmentation, which multiple providers had attributed to dermatoheliosis or photoaging. She highlighted, however, key photoprotected areas, such as the conchal bowls of the ears, also demonstrated blue-gray discoloration. The clinical differential diagnoses included lichen planus pigmentosus and argyria, yet the characteristic histopathologic features of these entities were not present on skin biopsy.

Instead, histologic examination revealed wavy deposits within the dermis that stained basophilic on Hematoxylin and Eosin and blue-black with Verhoeff Van Gieson (VVG) staining. Basophilic collagen fibers and altered deposits of elastic fibers have been reported as early-stage findings of ochronosis,3 in contrast to the classic late-stage yellow-brown banana-shaped collagen fibers. Based on these findings the patient was diagnosed with endogenous ochronosis/alkaptounuria, a genodermatosis characterized by impaired breakdown of tyrosine and phenylalanine.

In conclusion, Dr. Sokumbi emphasized how dermatologists are often uniquely positioned to diagnose systemic disease through careful evaluation of skin findings. Both cases underscored the importance of CPC. She encouraged repeating skin biopsies when the leading diagnosis remains unclear and collaborating with colleagues across specialties to ensure comprehensive management of systemic disease.

This session summary was written by Nagasai Adusumilli, MD, MBA, chief resident physician in dermatology at the George Washington University School of Medicine and Health Sciences.

References

  1. Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol. 2015 Feb 10;33(5):411-8. PMID: 25422482.
  2. Camargo K, Pinkston O, Abril A, Sluzevich JC. Xanthomatous multicentric reticulohistiocytosis: an underrecognized variant. J Clin Rheumatol. 2018 Aug;24(5):285-287. PMID: 29239933.
  3. Chowdary S, Mahalingam M, Vashi NA. Reading between the layers: early histopathological findings in exogenous ochronosis. Am J Dermatopathol. 2014 Dec;36(12):989-91.PMID: 25415140.

Pain Management & Wound Care in HS

By ODAC Sessions

pain management in hidradenitis suppurativa

At the 2026 ODAC Dermatology Conference in Orlando, hidradenitis suppurativa (HS) expert Hadar Lev-Tov, MD, gave a high-yield, practice-focused lecture on two frequently underappreciated pillars of HS care: pain management and wound care. According to Dr. Lev-Tov, addressing these areas is essential to improving quality of life and overall outcomes for patients with HS.

Pain as a Core Component of HS Care
Dr. Lev-Tov emphasized that pain is not a secondary symptom of HS but a central driver of disease burden. A large proportion of patients experience moderate to severe pain, which often impacts quality of life more than objective disease severity. Despite this, pain remains underrecognized and undertreated in dermatology clinics. Because dermatologists serve as the primary physicians for most HS patients, Dr. Lev-Tov stressed that pain management must be viewed as an integral part of HS care. Uncontrolled pain also increases the risk of long-term opioid use, an association that persists even after adjusting for confounders.

A Multimodal, Bio-Psycho-Social Approach
To address chronic HS pain, Dr. Lev-Tov advocated for a multimodal strategy rooted in a bio-psycho-social framework. Pharmacologic management should follow a stepwise approach, beginning with topical or systemic NSAIDs and acetaminophen. For neuropathic pain, agents such as gabapentin, pregabalin, TCAs, and SNRIs (including duloxetine) may be effective. Short courses of tramadol or other short-acting opioids can be considered for acute breakthrough pain, with strict limits on quantity. Procedural interventions, such as intralesional triamcinolone or punch deroofing, and referral to pain specialists should be considered for refractory cases.

Equally important are non-pharmacologic therapies, which form the foundation of chronic pain management. These include physical activation strategies (physical therapy, yoga, low-intensity aerobic exercise), behavioral interventions (cognitive behavioral therapy and mindfulness), and adjunctive techniques (massage, acupuncture, and chiropractic care).

Wound Care: Small Details, Big Impact
The second half of the presentation focused on wound care, which Dr. Lev-Tov described as critical to patient comfort and daily functioning. While medical and surgical treatment address disease control, appropriate wound care can dramatically improve quality of life—and poor dressing choices can undermine even the best treatment plans.

Key pearls included selecting dressings based on wound depth and exudate level, with practical guidance on the use of foams, hydrocolloids, gelling fibers, calcium alginates, and superabsorbent dressings. Dr. Lev-Tov also highlighted evidence supporting wide excision with healing by secondary intent, noting excellent outcomes even for large HS wounds. Dedicated HS wound care systems, such as HidraWear, can further enhance comfort, confidence, and ease of use.

Additional surgical pearls included continuing biologic therapy through HS surgery, recognizing and managing hypergranulation tissue, and using chemical debridement, topical corticosteroids, or mechanical debulking when needed.

Takeaway
Dr. Lev-Tov’s lecture on pain management and wound care in HS reinforced that effective HS care extends beyond inflammation control. Pain management is essential—not optional—and thoughtful, individualized wound care plays a major role in improving patient quality of life. By embracing a multimodal pain strategy and a structured approach to wound dressing selection, dermatologists can make a meaningful difference for patients living with HS.

This session summary was written by Dr. Ryan Gall and published on Next Steps in Derm.

Vulvar Dermatology Lessons: ODAC in the News

By ODAC Sessions

vulvar dermatology

Vulvar disease demands careful exams, patient education, and thoughtful, individualized management. This article by The Dermatology Digest encapsulates Dr. Emily Murphy’s ODAC session on lessons from the vulvar dermatology clinic. Dr. Murphy is a dermatologist and director of the Vulvar Health Program at the George Washington University School of Medicine and Health Sciences.

In the session, Dr. Murphy shared practical, high-yield pearls, addressing vulvar health topics, including lichen sclerosus, underlying infections, and the effects of low estrogen. She outlined six lessons for dermatology clinicians in treating vulvar disease.

Additional news coverage of ODAC is forthcoming. Stay tuned!

ODAC Expands Advisory Team

By ODAC Sessions

ODAC Advisory Team

The ODAC Advisory Team is growing!

Jennifer Soung, MD, FAAD, will serve as a medical dermatology advisor. Dr. Soung is a dermatologist in private practice in Santa Ana, Calif., and an associate professor at Harbor-UCLA Medical Center.

“Education has always been at the heart of my work in dermatology, and I have long believed that high-quality education is the foundation of exceptional patient care,” Dr. Soung says. “As ODAC’s medical dermatology advisor, I’m excited to collaborate with the advisory team to further strengthen medical dermatology education—bringing evidence-based insights, clinical relevance, and my enthusiasm, expertise, and genuine joy for dermatology to colleagues across the field.”

Vishal A. Patel, MD, FACMS, will serve as a conference co-chair. Dr. Patel, a longtime faculty member, was previously ODAC’s guest advisor for surgical dermatology. He is an associate professor of dermatology and director of the Cutaneous Oncology Program at GWU School of Medicine & Health Sciences.

“I’m honored to step into the role of ODAC conference co-chair and help shape the next chapter of this remarkable meeting,” Dr. Patel says. “Serving as a special advisor has been a privilege, and I’m proud of the work we’ve already done to elevate the conference’s impact. I’m excited to build on that momentum by expanding our surgical dermatology and cutaneous oncology offerings with innovative, practical education that empowers clinicians to elevate patient care.”

ODAC Conference Co-Chair Adam Friedman, MD, FAAD, says these changes to the ODAC Advisory Team make for an exciting time for ODAC. “In Dr. Patel’s expanded role as co-chair, and Dr. Soung as medical advisor, they will no doubt further strengthen ODAC’s mission to deliver innovative AND practical education that truly meets the needs of today’s dermatology community.”

“ODAC continues to evolve with the times as dermatology changes,” says ODAC Conference Co-Chair Susan H. Weinkle, MD, FAAD. “We are proud to have Drs. Patel and Soung in their new roles on the advisory team as we continue to enhance our surgical and medical dermatology offerings. This is a forward-thinking change that will lead to improved patient care.”

Save the Date! ODAC 2027 will take place Friday, January 15, through Monday, January 18, 2027, in Orlando at the Signia by Hilton Orlando Bonnet Creek.

Mastering Biologic Access in Dermatology: ODAC Preview

By ODAC Sessions

biologic access

Biologics are effective, but getting access can be a challenge. For smoother starts and fewer insurance roadblocks, attend this 30-minute ODAC CME workshop, “Mastering Biologic Access in Dermatology: What Your Biologics Coordinator Wants You to Know,” on Saturday, January 17, from 5:15-5:45 p.m.

Heather Sawrey, biologics coordinator for the GWU Department of Dermatology, brings 17 years of real-world experience helping patients access biologic therapies. She’ll cover best practices for prior authorizations, patient education, pharma support programs, and how clinical teams can work together to reduce delays. Practical, actionable, and time-efficient — perfect for dermatologists, nurses, and clinic staff. (Aren’t yet registered for ODAC? Register today!)

Dermoscopy Beyond the Basics: ODAC Preview

By ODAC Sessions

dermoscopy

Ready to decode the toughest dermoscopic cases?

Join Jennifer Stein, MD, PhD, FAAD, for “Dermoscopy Beyond the Basics: Identifying Challenging and Atypical Lesions” on Sunday, January 18, from 3:45–4:30 p.m. at ODAC 2026.

This focused CME workshop will highlight real-world, high-yield approaches to recognizing atypical presentations and improving diagnostic confidence. Perfect for dermatologists and trainees who want practical, clinic-ready strategies. You won’t want to miss it!

GLP-1 Panel: ODAC Preview

By ODAC Sessions

GLP-1 agonists

Curious how GLP‑1 agonists fit into holistic dermatology care? Don’t miss this rapid-fire, 25‑minute panel in the Opening General Session at ODAC 2026 (Jan 16):  

“GLP‑1 Agonists in Cutaneous Medicine: Rapid‑Fire Insights on Comorbidities, Safety, and Aesthetic Considerations”  

Moderator: Adam Friedman, MD, FAAD  

Panelists: Jennifer Soung, MD, FAAD; Steven Daveluy, MD, FAAD; Sarah Jackson, MD, FAAD

What to expect:

– Focused review of metabolic and inflammatory comorbidities in psoriasis and HS  

– Practical evidence and tips for integrating GLP‑1 therapy to address cardiometabolic risk  

– Discussion of potential aesthetic consequences (hair changes, skin laxity) and safety monitoring  

– Multidisciplinary strategies you can use in clinic

This concise, discussion‑driven session is ideal for dermatologists, trainees, and multidisciplinary colleagues wanting actionable, real‑world guidance. See you there!

(Are you just now thinking about ODAC? Don’t miss out: Register today!)

JDD Video Abstract with ODAC Faculty Dr. Hilary Baldwin

By Uncategorized

acneceuticals

ODAC faculty are not only experts in dermatology – many are involved hands-on with the latest dermatologic research.

Case in point: Dr. Hilary Baldwin. A prolific researcher, Dr. Baldwin is a sought-after speaker on a variety of dermatology topics. At ODAC 2026, Dr. Baldwin will share approaches for treating keloids, provide an acne update for 2026, and address the role of cosmeceuticals in barrier repair.

If you’re looking for a sneak peak, check out Dr. Baldwin’s JDD Video Abstract about a recent study in which she was the lead author, “Real-World Clinical Case Series Utilizing Acneceuticals as Monotherapy, Adjunctive, or Maintenance Therapy for Acne Vulgaris.”

Watch as Dr. Baldwin gives the background on the need for and classification of acneceuticals. Find out the real-world data on the effectiveness of acneceuticals in the treatment of acne vulgaris, both as monotherapy and in conjunction with prescription therapies. Learn from Dr. Baldwin on how acneceuticals can help with patient engagement in their treatment. Plus find out her takeaways from the study and how dermatologists may best recommend acneceuticals for their acne patients.

Be sure to register for ODAC to learn from Dr. Baldwin in-person.